Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Muscle Invasive Bladder Cancer × RC48 antibody × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Stomach Neoplasms 1 Salivary Gland Neoplasms 1 Ovarian Neoplasms 1 Muscle Invasive Bladder Cancer 1 HER2-positive Metastatic Breast Cancer 1 HER2-low Breast Cancer 1 Cervical Cancer Recurrent 1 Breast Neoplasms 1

Interventions

toripalimab 1 tislelizumab 1 liposomal doxorubicin 1 disitamab vedotin 1 Surgical Procedures, Operative 1 Rutin 1 Radiation 1 RC48 antibody 1 Gemcitabine 1 Cystectomy 1 Cisplatin 1 Chemoradiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05979740 2023-08-31

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

RenJi Hospital

Phase 2 Unknown

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡